Evidence map›Paper›PMID 39650256›Full record

ArticleSouthern African journal of infectious diseases2024

Comparison of SARS-CoV-2 molecular results from the first two COVID-19 waves in Gauteng.

Kreshalen Govender, Rendani T Mafuyeka, Azwidowi Lukhwareni, Pieter Meyer

Abstract read
In one paragraph

Article in Southern African journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kreshalen GovenderDepartment of Medical Virology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.ORCID https://orcid.org/0000-0003-4196-655X
Rendani T MafuyekaDepartment of Molecular Virology, Faculty of Virology, Ampath Laboratories Inc., Pretoria, South Africa.ORCID https://orcid.org/0000-0003-0056-1329
Azwidowi LukhwareniDepartment of Medical Virology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.ORCID https://orcid.org/0000-0002-4456-2270
Pieter MeyerDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.ORCID https://orcid.org/0000-0002-7318-1055

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Laboratory-based molecular assays return cycle threshold (Ct) values for each gene target. There is limited hyperlocal information describing the Ct, age and sex trends during the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) waves in South Africa. Objectives: To analyse the demographic and Ct value trends of SARS-CoV-2 molecular assays from two South African hospitals. Method: The Seegene Allplex 2019-nCoV™ results from the first two waves (June-July 2020 and November 2020-January 2021) from two major hospitals in Gauteng, South Africa, were extracted from the laboratory information system. Demographic variables and Ct values were analysed. Results: Overall, 2391 samples were analysed over two waves. In both waves, more women were tested than men; 68.4% versus 31.2% in the first wave and 59.8% versus 39.7% in the second wave. Differences in Ct values among the age groups were non-significant overall; however, most median Ct values in all age groups were < 30. Men had lower median Ct values in the first wave, but this trend reversed in the second wave ( Conclusion: Patients tested in the first wave had lower Ct values. All age groups in both waves demonstrated infectivity potential; the demographic analysis agreed with South Africa's coronavirus disease 2019 (COVID-19) epidemiological trends in both waves. Contribution: Granular insight into the basic demographic variables and Ct trends of SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) results within and between SARS-CoV-2 waves in South Africa.

Indexed as

COVID‒19cycle thresholddemographicsRT‒PCRSARS-CoV-2

Identifiers

PMID39650256
PMCPMC11622115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.